Evidence map›Paper›PMID 31186416›Full record

ArticleNature communications2019

Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells.

Kim R Kampen, Laura Fancello, Tiziana Girardi, Gianmarco Rinaldi, Mélanie Planque, Sergey O Sulima, Fabricio Loayza-Puch, Benno Verbelen, Stijn Vereecke, Jelle Verbeeck and 9 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 105 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Ribosome specialization by cancer-associated ribosomal protein mutations: progress made and open questions.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Metabolic heterogeneity in cancer.Nature metabolism · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 3 countries.

Kim R KampenLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0001-5065-1272
Laura FancelloLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0003-4708-4080
Tiziana GirardiLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0002-1344-8459
Gianmarco RinaldiLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0001-5191-4580
Mélanie PlanqueLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Herestraat 49, 3000, Leuven, Belgium.
Sergey O SulimaLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium.
Fabricio Loayza-PuchTranslational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2999-8594
Benno VerbelenLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium.
Stijn VereeckeLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0001-8414-8907
Jelle VerbeeckLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium.
Joyce Op de BeeckLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium.
Jonathan RoyaertLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium.
Pieter VermeerschDepartment of Laboratory Medicine, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
David CassimanDepartment of Gastroenterology-Hepatology and Metabolic Center, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0002-6154-0970
Jan CoolsLaboratory of Molecular Biology of Leukemia, VIB-KU Leuven Center for Cancer Biology, VIB, Herestraat 49, 3000, Leuven, Belgium.
Reuven AgamiDepartment of Pediatric Oncology/Hematology, Erasmus Medical Center, Wytemaweg 80, 3015 CN, Rotterdam, the Netherlands.
Mark FiersLaboratory for the Research of Neurodegenerative Diseases, VIB-KU Leuven Center for Brain & Disease Research, Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0001-5694-2409
Sarah-Maria FendtLaboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Herestraat 49, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0001-6018-9296
Kim De KeersmaeckerLaboratory for Disease Mechanisms in Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Herestraat 49, 3000, Leuven, Belgium. kim.dekeersmaecker@kuleuven.be.ORCID http://orcid.org/0000-0002-7420-9531
KU Leuven · BEVIB-KU Leuven Center for Cancer Biology · BEGerman Cancer Research Center · DEThe Netherlands Cancer Institute · NLVIB-KU Leuven Center for Brain & Disease Research · BE

Funding

EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: "Ideas" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013)) 334946Onderzoeksraad, KU Leuven (Research Council, KU Leuven) C14/18/104Stichting Tegen Kanker (Belgian Foundation Against Cancer) 2012-176Stichting Tegen Kanker (Belgian Foundation Against Cancer) 2016-775Stichting Tegen Kanker (Belgian Foundation Against Cancer) 2016-801
6 · The paper itself

Abstract

Somatic ribosomal protein mutations have recently been described in cancer, yet their impact on cellular transcription and translation remains poorly understood. Here, we integrate mRNA sequencing, ribosome footprinting, polysomal RNA sequencing and mass spectrometry datasets from a mouse lymphoid cell model to characterize the T-cell acute lymphoblastic leukemia (T-ALL) associated ribosomal RPL10 R98S mutation. Surprisingly, RPL10 R98S induces changes in protein levels primarily through transcriptional rather than translation efficiency changes. Phosphoserine phosphatase (PSPH), encoding a key serine biosynthesis enzyme, was the only gene with elevated transcription and translation leading to protein overexpression. PSPH upregulation is a general phenomenon in T-ALL patient samples, associated with elevated serine and glycine levels in xenograft mice. Reduction of PSPH expression suppresses proliferation of T-ALL cell lines and their capacity to expand in mice. We identify ribosomal mutation driven induction of serine biosynthesis and provide evidence supporting dependence of T-ALL cells on PSPH.

Indexed as

MutationAnimalsCell LineGene Expression ProfilingGlycineMicePhosphoric Monoester HydrolasesPolyribosomesPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProtein BiosynthesisRibosomal Protein L10Ribosomal ProteinsRibosomesRNA, MessengerSequence Analysis, RNASerineGlycinePhosphoric Monoester Hydrolasesphosphoserine phosphataseRibosomal ProteinsRNA, MessengerRpl10 protein, mouseSerine

Identifiers

PMID31186416
PMCPMC6559966
OpenAlexW2950301364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.